Tags

Type your tag names separated by a space and hit enter

Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients.
Am J Kidney Dis. 2005 Dec; 46(6):1099-106.AJ

Abstract

BACKGROUND

Hyperlipidemic factors contribute to the high cardiovascular risk in hemodialysis patients. Soy protein has decreased some atherogenic lipid concentrations in subjects with normal renal function. This study evaluates the effect of soy protein on serum lipid profiles in hyperlipidemic and normolipidemic hemodialysis patients.

METHODS

Nineteen hyperlipidemic and 18 normolipidemic hemodialysis patients were enrolled in a randomized, double-blind, placebo-controlled, clinical trial. After a 4-week run-in phase, subjects in each category were randomly assigned to 2 groups. Thirty grams of isolated soy protein or milk protein was consumed daily as a beverage at breakfast or postdialysis for 12 weeks.

RESULTS

In hyperlipidemic subjects, soy protein intake significantly decreased total cholesterol levels by 18.6% (95% confidence interval [CI], -11.4 to -25.8; P = 0.04), triglyceride levels by 43.1% (95% CI, -34.0 to -52.2; P = 0.02), non-high-density lipoprotein cholesterol levels by 23.6% (95% CI, -14.7 to -32.5; P < 0.01), apolipoprotein B levels by 15.4% (95% CI, -5.4 to -25.4; P = 0.01), and insulin levels by 49.8% (95% CI, -23.3 to -66.1; P < 0.01). Low-density lipoprotein cholesterol concentration was decreased significantly (-25.8%; 95% CI, -8.3 to -42.7; P = 0.01), and high-density lipoprotein cholesterol level was increased significantly (17%; 95% CI, 2 to 32.0; P = 0.03), but there was no significant difference compared with the milk protein group (-5.5% +/- 16.9% and 7.0% +/- 11.8%, respectively). There were no significant changes in serum lipid and lipoprotein concentrations in normolipidemic subjects.

CONCLUSION

These results indicate soy protein substitution has lipid-lowering effects in hyperlipidemic hemodialysis patients. However, soy protein intake had little effect on plasma lipid levels in normolipidemic hemodialysis patients.

Authors+Show Affiliations

Department of Nutrition and Health Sciences, Taipei Medical University, Cathay General Hospital, Taipei, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16310576

Citation

Chen, Shu-Tzu, et al. "Variable Effects of Soy Protein On Plasma Lipids in Hyperlipidemic and Normolipidemic Hemodialysis Patients." American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, vol. 46, no. 6, 2005, pp. 1099-106.
Chen ST, Ferng SH, Yang CS, et al. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients. Am J Kidney Dis. 2005;46(6):1099-106.
Chen, S. T., Ferng, S. H., Yang, C. S., Peng, S. J., Lee, H. R., & Chen, J. R. (2005). Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, 46(6), 1099-106.
Chen ST, et al. Variable Effects of Soy Protein On Plasma Lipids in Hyperlipidemic and Normolipidemic Hemodialysis Patients. Am J Kidney Dis. 2005;46(6):1099-106. PubMed PMID: 16310576.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients. AU - Chen,Shu-Tzu, AU - Ferng,Shyang-Hwa, AU - Yang,Chwei-Shiun, AU - Peng,Sheng-Jeng, AU - Lee,Huei-Rong, AU - Chen,Jiun-Rong, PY - 2005/06/27/received PY - 2005/08/25/accepted PY - 2005/11/29/pubmed PY - 2006/2/4/medline PY - 2005/11/29/entrez SP - 1099 EP - 106 JF - American journal of kidney diseases : the official journal of the National Kidney Foundation JO - Am. J. Kidney Dis. VL - 46 IS - 6 N2 - BACKGROUND: Hyperlipidemic factors contribute to the high cardiovascular risk in hemodialysis patients. Soy protein has decreased some atherogenic lipid concentrations in subjects with normal renal function. This study evaluates the effect of soy protein on serum lipid profiles in hyperlipidemic and normolipidemic hemodialysis patients. METHODS: Nineteen hyperlipidemic and 18 normolipidemic hemodialysis patients were enrolled in a randomized, double-blind, placebo-controlled, clinical trial. After a 4-week run-in phase, subjects in each category were randomly assigned to 2 groups. Thirty grams of isolated soy protein or milk protein was consumed daily as a beverage at breakfast or postdialysis for 12 weeks. RESULTS: In hyperlipidemic subjects, soy protein intake significantly decreased total cholesterol levels by 18.6% (95% confidence interval [CI], -11.4 to -25.8; P = 0.04), triglyceride levels by 43.1% (95% CI, -34.0 to -52.2; P = 0.02), non-high-density lipoprotein cholesterol levels by 23.6% (95% CI, -14.7 to -32.5; P < 0.01), apolipoprotein B levels by 15.4% (95% CI, -5.4 to -25.4; P = 0.01), and insulin levels by 49.8% (95% CI, -23.3 to -66.1; P < 0.01). Low-density lipoprotein cholesterol concentration was decreased significantly (-25.8%; 95% CI, -8.3 to -42.7; P = 0.01), and high-density lipoprotein cholesterol level was increased significantly (17%; 95% CI, 2 to 32.0; P = 0.03), but there was no significant difference compared with the milk protein group (-5.5% +/- 16.9% and 7.0% +/- 11.8%, respectively). There were no significant changes in serum lipid and lipoprotein concentrations in normolipidemic subjects. CONCLUSION: These results indicate soy protein substitution has lipid-lowering effects in hyperlipidemic hemodialysis patients. However, soy protein intake had little effect on plasma lipid levels in normolipidemic hemodialysis patients. SN - 1523-6838 UR - https://www.unboundmedicine.com/medline/citation/16310576/Variable_effects_of_soy_protein_on_plasma_lipids_in_hyperlipidemic_and_normolipidemic_hemodialysis_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0272-6386(05)01330-2 DB - PRIME DP - Unbound Medicine ER -